Business context and reporting period
This is On Assignment, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2014; the filing does not identify Everforth Inc. as the registrant. On Assignment provides contract, contract-to-hire, and direct-hire staffing in technology, healthcare, and life sciences. Its reportable segments are Apex, Oxford, Physician, and Life Sciences Europe. Comparisons below are year over year unless stated otherwise.
Financial results and position
| Metric | Third quarter 2014 | Nine months 2014 |
|---|---|---|
| Revenue | $477.8 million, +13.4% | $1,385.7 million, +14.7% |
| Gross profit / margin | $155.6 million / 32.6%; margin +2.4 percentage points | $445.9 million / 32.2%; margin +2.5 percentage points |
| Operating income | $40.9 million, +14.6% | $106.8 million, +18.3% |
| Income from continuing operations | $22.0 million, versus $19.5 million | $56.8 million, versus $36.9 million |
| Net income / diluted EPS | $22.0 million / $0.41, versus $20.2 million / $0.37 | $56.7 million / $1.03, versus $52.1 million / $0.96 |
| Operating cash flow | Not presented separately for the quarter | $68.0 million, versus $73.9 million |
Third-quarter SG&A was $108.7 million, or 22.8% of revenue, versus $86.3 million, or 20.5%. Nine-month SG&A was $320.8 million, or 23.1% of revenue, versus $252.5 million, or 20.9%. Management attributed the higher ratio in part to CyberCoders’ higher-margin, higher-SG&A business mix. Nine-month results in 2013 included a $15.0 million loan-cost write-off; 2013 net income also included a $14.4 million after-tax gain on discontinued operations.
At September 30, 2014, cash was $29.9 million, working capital was $199.4 million, total debt was $403.7 million, and stockholders’ equity was $643.0 million. The company had $62.1 million available on its revolving credit facility, a funded-debt-to-consolidated-EBITDA ratio of 2.06:1, and was in compliance with debt covenants. Cash declined $7.5 million from year-end 2013. Nine-month investing cash use was $13.7 million, including $14.3 million of property and equipment purchases; financing cash use was $61.0 million, including $68.2 million of share repurchases. The company estimated 2014 capital expenditures of approximately $19.7 million.
Material changes and segment trends
- Revenue growth was 7.2% for the quarter and 8.5% for the nine months on a pro forma basis, excluding the timing effect of the CyberCoders and Whitaker acquisitions. Organic growth was 6.8% and 8.1%, respectively; the acquisitions contributed $27.6 million and $79.2 million of revenue.
- Direct-hire and conversion-fee revenue rose to 5.0% of third-quarter revenue from 1.7% a year earlier, and to 4.8% for the nine-month period from 1.7%. CyberCoders accounted for much of this increase.
- In the quarter, Apex revenue increased 10.5%, Oxford 17.3% reported (1.3% pro forma), and Physician 33.3% reported (4.1% pro forma); Life Sciences Europe declined 0.9%. Nine-month reported revenue rose across all four segments, although Oxford and Physician growth was largely acquisition-related on a pro forma basis.
- Gross-margin expansion reflected higher direct-hire mix and improved contract margins. Oxford’s reported margin increased substantially, largely due to CyberCoders’ direct-hire mix. Life Sciences Europe’s margin contracted, and Physician’s margin benefited in part from a medical-malpractice reserve reduction.
- Acquisitions of CyberCoders and Whitaker closed in December 2013 for stated purchase prices of approximately $98.6 million and $21.3 million, respectively. Purchase-price allocations remained subject to finalization. Goodwill was $574.0 million and identifiable intangible assets were $269.8 million at quarter-end.
Outlook, risks, and unusual items
- Management said working capital, available revolver capacity, and expected operating cash flows should be sufficient for debt service, working-capital needs, and capital expenditures over the next 12 months. No specific revenue or earnings guidance was provided.
- Seasonality typically reduces staffing demand in the first and fourth quarters and raises it in the second and third quarters. The company cited demand, recruiting and retention, competition, growth management, information systems, acquisition integration, strategic-plan execution, and litigation as risks to results.
- The credit facility requires quarterly Term A payments and certain mandatory prepayments; its maximum leverage ratio tightens from 3.75:1 at September 30, 2014 to 3.25:1 at June 30, 2015. A hypothetical 100-basis-point interest-rate change would affect annual interest expense by approximately $4.0 million before interest-rate-cap effects.
- The company repurchased 2.316 million shares for $68.2 million at an average $29.46 per share; $31.8 million remained under the $100 million, two-year authorization. Shares were retired.
- Potential acquisition contingent consideration was approximately $16.0 million through 2015; the recorded fair-value liability was $7.9 million. Workers’ compensation and medical-malpractice reserves depend on actuarial estimates. The company disclosed ordinary-course legal matters and did not expect their resolution to materially affect its financial statements.
- Foreign-currency translation reduced nine-month comprehensive income by $3.1 million. The company held $9.4 million of cash abroad and said it did not intend to repatriate it. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended issuer: this filing is for On Assignment, Inc., not Everforth Inc.
- Assess how much reported growth and margin expansion is attributable to acquisitions and direct-hire placements versus sustainable organic demand.
- Monitor accounts receivable, which increased to $296.5 million from $262.2 million at year-end, and operating cash flow, which fell year over year.
- Review leverage, covenant headroom, scheduled debt payments, and exposure to variable interest rates as the leverage limit tightens.
- Track the remaining share-repurchase authorization, acquisition earn-outs, reserve estimates, and final purchase-price allocations.